Search

The article explores how surgeons need to manage inaccurate Intraocular lens calculations, an extended postop recovery time and patient expectations. Topics include lens calculations is the surgical procedure itself and the postoperative healing period are not routine in the eyes; and surgeons have had success with extended depth-of-focus lenses.

At six months postoperatively, the uncorrected distance visual acuity was -0.01 ±0.06 logMAR (a little better than 20/20) in the SMILE eyes and -0.05 ± 0.10 (a little better still) in the LASIK eyes, while the corrected visual acuity was-0.07 ± 0.07 logMAR in the SMILE eyes and-0.08 ± 0.08 (a shade off of 20/16) in the LASIK eyes. "In comparison, surgeons cannot perform a repeat SMILE surgery on an eye that's already had SMILE", notes Dr. Manche. Dr. Manche just completed a randomized clinical trial of 40 patients who underwent wavefront-guided LASIK in one eye and SMILE in the fellow eye. [Extracted from the article]

The article offers information on how to handle dislocated intraocular lenses (IOLs). It mentions about the increasingly common etiology for late decentration of the capsule bag IOL complex as pars plana vitrectomy. It discusses that breakdown of the blood-aqueous barrier associated with the zonulysis.

The article highlights the current minimallyinvasive glaucoma surgery options. It mentions that minimally-invasive glaucoma surgery is intended to lower intraocular pressure with less tissue disruption than traditional glaucoma surgeries and also focuses on a variety of options and mechanisms of action to choose from ophthalmologists.

The article discusses the advantages and disadvantages associated with laser iridotomy and cataract surgery treatments for angle-closure patients. Reay Brown from Atlanta Ophthalmology Associates observed that it is easy to perform an iridotomy, which takes a couple of minutes, compared a cataract operation and both the treatments are not interchangeable. He said that the treatment choice are based on the severity of the patient's problem.

The article offers information on management of primary epiretinal membrane (ERM) that occurs together with cataracts. Eye specialist Vance Thompson highlights the significance of performing optical coherence tomography on every routine cataract surgery patient. It states that surgeons have to decide whether to perform a combined surgery or perform the cataract surgery first and address the epiretinal membrane at a later time.

The article discusses innovations in phaco technology. It is noted that phaco machines have undergone various upgrades to contribute in enhancing safety and efficacy of cataract surgery. It is stated that Alcon Centurion was introduced in 2013 that provides anterior chamber stability during each step of eye surgery. It is stated that Stellaris Elite has associated with with IBM to provide eyeTELLIGENCE, that provides expedited technical support and improved workflow for eye surgeons.

The article discusses the medication used in post-cataract surgery to avoid infection or inflammation. Topics covered include the disadvantages in using eye drops such as lack of compliance, contamination and incorrect administration, the application of intracameral antibiotic, and the downside in injections such as the strategy, emergence of edema and patient safety, and information about the phenylephrine and ketorolac injection Omidria.

The article focuses on the use of refractive surgery for the treatment of cataract. The preoperative and postoperative superficial keratectomy patient topography is demonstrated. Suggestions are also offered on the implant of contact lenses, correction of a refractive error and on the stability of refraction.

The article offers information on the management of zonular weakness during cataract surgery. It states that zonular weakness occurs due to pseudoexfoliation so the U.S. surgeons should determine the dilation of pupil and then compare the anterior chamber depth of the eye to its axial length. It further states that surgeons are using capsular tension rings and capsule hooks for managing zonular weakness.

The article discusses the efficiency of routine cataract surgery in treating cystoid macular edema (CME). CME is the most common cause of visual decline after uncomplicated cataract surgery and can have long-term consequences for patients. The incidence of CME after routine cataract surgery has not changed, but surgeons are gaining a better understanding of its impact on patients and how to prevent its occurrence.

The article reports on cataract procedures which are innovative and creative ways to minimize preoperative chair time. The 2005 ruling of the Centers for Medicare and Medicaid Services permits Medicare beneficiaries the option of upgrading to presbyopia-correcting IOLs has made the majority of cataract patients refractive surgery candidates.

The article scrutinizes various surgical procedures and techniques for patients with cataract. It mentions that the surgeons's goal is to let patients achieve emmetropia. It notes however that patients need to be educated on the difference between 20/20 vision and spectacle-free vision to counter high expectations. It states that the factors in achieving emmetropia will depend on patient factors and surgeon technique.

The article presents tips in performing safe, effective phacoemulsification with the newest machines and options. Accordingly, trends point to microincision, which has offered the benefits of reduced astigmatism, safety of intraoperation as well as improved rate of wound sealing. According to Mark Packer, a clinical associate professor at Oregon Health and Sciences University (OHSI), the transverse motion of the phaco tip is able to do more efficient consumption of lens material.

The article discusses the effect of cataract surgery to people with dry eye diseases in the U.S. Reportedly, such treatment makes pre-existing dry eye and cause dry eye to patients with well corneas. According to physician Eric Donnenfeld, elderly patients are more prone to develop such damage especially with their sensitivity to the medications provided during cataract operation.

Reports on the implications for the approval of Xibrom, a bromfenac ophthalmic solution used for the treatment of ocular inflammation after cataract surgery by the U.S. Food and Drug Administration. Availability of the ophthalmic solution; Efficacy of the solution in improving pain, eye inflammation and visual acuity; Mechanism of action of Xibrom.